PMID- 18086761
OWN - NLM
STAT- MEDLINE
DCOM- 20080304
LR  - 20131121
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 16
IP  - 12
DP  - 2007 Dec
TI  - Plasma isoflavones and fibrocystic breast conditions and breast cancer among 
      women in Shanghai, China.
PG  - 2579-86
AB  - BACKGROUND: Proliferative benign breast conditions are associated with elevated 
      risk of breast cancer, whereas nonproliferative conditions are not strongly 
      associated with risk. Factors acting before onset of hyperplasia might be 
      associated with both benign conditions and breast cancer, whereas those on the 
      proliferative disease-to-cancer pathway would be associated only with cancer. Soy 
      isoflavone exposure may influence breast cancer risk, but little is known of its 
      association with benign conditions. MATERIALS AND METHODS: We examined possible 
      relationships between plasma genistein and daidzein concentrations and risk of 
      breast disease in women, in a breast self-examination trial in Shanghai, China, 
      diagnosed with breast cancer (n = 196) or a benign breast condition (n = 304), 
      and 1,002 age-matched controls with no known breast disease. Benign conditions 
      were classified as nonproliferative (n = 131) or proliferative with or without 
      atypia (n = 173). RESULTS: Isoflavone concentrations were inversely associated 
      with risk of nonproliferative and proliferative benign fibrocystic conditions, as 
      well as with breast cancer, both with and without concomitant proliferative 
      changes in ipsilateral noncancerous mammary epithelium (P(trend) < 0.01 for all 
      comparisons with controls). Women in the highest quartile of plasma genistein 
      (>76.95 ng/mL) were less likely to have breast cancer (odds ratio, 0.26; 95% 
      confidence interval, 0.13-0.50) or benign conditions (odds ratio, 0.40; 95% 
      confidence interval, 0.23-0.70) compared with women in the lowest quartile (<9.42 
      ng/mL). Observed risks for breast cancer with and without surrounding 
      proliferative changes were not different, respectively, from observed risks for 
      benign proliferative and nonproliferative conditions alone. CONCLUSION: 
      Isoflavone exposure was inversely associated with fibrocystic breast conditions 
      and breast cancer, and the results suggest that effects on cancer risk occur 
      early in carcinogenesis.
FAU - Lampe, Johanna W
AU  - Lampe JW
AD  - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
      WA 98109, USA. jlampe@fhcrc.org
FAU - Nishino, Yoshikazu
AU  - Nishino Y
FAU - Ray, Roberta M
AU  - Ray RM
FAU - Wu, Chunyuan
AU  - Wu C
FAU - Li, Wenjin
AU  - Li W
FAU - Lin, Ming-Gang
AU  - Lin MG
FAU - Gao, Dao Li
AU  - Gao DL
FAU - Hu, Yongwei
AU  - Hu Y
FAU - Shannon, Jackilen
AU  - Shannon J
FAU - Stalsberg, Helge
AU  - Stalsberg H
FAU - Porter, Peggy L
AU  - Porter PL
FAU - Frankenfeld, Cara L
AU  - Frankenfeld CL
FAU - Wahala, Kristiina
AU  - Wahala K
FAU - Thomas, David B
AU  - Thomas DB
LA  - eng
GR  - R01 CA75332/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Isoflavones)
RN  - 0 (Soybean Proteins)
RN  - 6287WC5J2L (daidzein)
RN  - DH2M523P0H (Genistein)
SB  - IM
MH  - Adult
MH  - Breast Neoplasms/*blood/epidemiology
MH  - Case-Control Studies
MH  - China/epidemiology
MH  - Chromatography, Liquid
MH  - Diet
MH  - Female
MH  - Fibrocystic Breast Disease/*blood/epidemiology
MH  - Genistein/*blood
MH  - Humans
MH  - Isoflavones/*blood
MH  - Mass Spectrometry
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Soybean Proteins
EDAT- 2007/12/19 09:00
MHDA- 2008/03/05 09:00
CRDT- 2007/12/19 09:00
PHST- 2007/12/19 09:00 [pubmed]
PHST- 2008/03/05 09:00 [medline]
PHST- 2007/12/19 09:00 [entrez]
AID - 16/12/2579 [pii]
AID - 10.1158/1055-9965.EPI-07-0368 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2579-86. doi: 
      10.1158/1055-9965.EPI-07-0368.